Related Experiment Videos
Chemotherapy for hormone refractory prostate cancer
1Department of Internal Medicine, University of Michigan School of Medicine, Ann Arbor, USA. dcsmith@umich.edu
The Urologic Clinics of North America
|June 11, 1999
Summary
New combination therapies show promise for hormone refractory prostate cancer, offering palliative benefits and improving quality of life. Further clinical trials are needed to establish efficacy and impact survival rates.
Area of Science:
- Oncology
- Urology
Background:
- Hormone refractory prostate cancer presents challenges in treatment.
- Existing therapies offer palliative benefits but do not significantly impact survival.
Purpose of the Study:
- To review new combination therapies for hormone refractory prostate cancer.
- To assess the palliative benefits and potential for earlier application of these novel treatments.
Main Methods:
- Review of current therapeutic strategies and clinical trial outcomes.
- Analysis of combination regimens targeting specific prostate cancer cellular pathways.
Main Results:
- New combination therapies demonstrate significant palliative activity, improving quality of life.
- Regimens like mitoxantrone and prednisone show notable benefits.
- No current regimen significantly affects survival or is considered standard therapy.
Conclusions:
- Novel combination therapies challenge skepticism regarding chemotherapy for advanced prostate cancer.
- Earlier application of these regimens may improve morbidity and mortality.
- Clinical trials are crucial for developing effective future therapies.